Aktis Oncology aims to raise up to $317.7 million in upsized US IPO

Jan 7 (Reuters) – Cancer ‍drug developer Aktis Oncology ‌said ‌on Wednesday it was aiming to ​raise ‍as ​much ​as $317.7 million ‍in its upsized initial ‍public offering in the ‍U.S.

(Reporting ‍by ​Arasu ​Kannagi ⁠Basil ‌in Bengaluru; Editing by Sahal ⁠Muhammed)